Navana Pharmaceuticals Inkomsten in het verleden
We zijn nog bezig met het verwerken van het laatste winstrapport van dit bedrijf
Verleden criteriumcontroles 5/6
Navana Pharmaceuticals has been growing earnings at an average annual rate of 26.4%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 19.7% per year. Navana Pharmaceuticals's return on equity is 9.7%, and it has net margins of 6.8%.
Belangrijke informatie
26.4%
Groei van de winst
18.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 11.0% |
| Inkomstengroei | 19.7% |
| Rendement op eigen vermogen | 9.7% |
| Nettomarge | 6.8% |
| Laatste winstupdate | 31 Mar 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Navana Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Mar 24 | 6,504 | 440 | 2,127 | 0 |
| 31 Dec 23 | 6,258 | 438 | 2,034 | 0 |
| 30 Sep 23 | 6,002 | 404 | 1,971 | 0 |
| 30 Jun 23 | 5,706 | 357 | 1,875 | 0 |
| 31 Mar 23 | 5,331 | 331 | 1,648 | 0 |
| 31 Dec 22 | 5,053 | 294 | 1,649 | 0 |
| 30 Sep 22 | 4,890 | 285 | 1,610 | 0 |
| 30 Jun 22 | 4,759 | 274 | 1,591 | 0 |
| 30 Jun 21 | 3,607 | 202 | 1,265 | 0 |
| 30 Jun 20 | 3,149 | 137 | 1,135 | 0 |
Kwaliteitswinsten: NAVANAPHAR has high quality earnings.
Groeiende winstmarge: NAVANAPHAR's current net profit margins (6.8%) are higher than last year (6.2%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: NAVANAPHAR's earnings have grown significantly by 26.4% per year over the past 5 years.
Versnelling van de groei: NAVANAPHAR's earnings growth over the past year (33.1%) exceeds its 5-year average (26.4% per year).
Winst versus industrie: NAVANAPHAR earnings growth over the past year (33.1%) exceeded the Pharmaceuticals industry -2.8%.
Rendement op eigen vermogen
Hoge ROE: NAVANAPHAR's Return on Equity (9.7%) is considered low.